ArticleAnnals of medicine and surgery (2012)2025
Efficacy of pirfenidone in fibrotic hypersensitivity pneumonitis: a systematic review and meta-analysis of randomized controlled trials.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibrotic hypersensitivity pneumonitis (HP), a progressive and irreversible interstitial lung disease (ILD), carries a significant risk of morbidity and mortality due to the narrow range of therapeutic options available. The role of anti-fibrotic drugs for this disease entity has been called into question, and the results of various studies have been unclear so far. This meta-analysis evaluates the efficacy of the drug pirfenidone, an anti-fibrotic agent in fibrotic HP, to document a clear consensus of the benefits in disease outcomes. Materials and methods: PubMed, Scopus, and MEDLINE were searched for the randomized controlled trials (RCTs) evaluating the efficacy of pirfenidone in fibrotic HP against a placebo. Data were extracted from the RCTs that met the inclusion criteria, and pooled analysis was performed to evaluate the significance of % Predicted FVC (forced vital capacity), % Predicted DLCO (diffusion capacity of carbon monoxide), and change in SGRQ (George's respiratory questionnaire) at the completion of the trial. Results: No significant change was observed in the % predicted FVC [Mean difference (MD): 3.65; 95% Confidence interval (CI): -1.63, 8.94; Conclusion: Pirfenidone was not associated with a significant change in the lung function metrics, but it has been shown to improve the quality of life, as evidenced by a significant decrease in the SGRQ score.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.